---
title: "Global and Regional Trends in Chronic Kidney Disease Incidence, 1992–2021, with Projections to 2031"
id: "plos-one-20-temporal-trends-in-the-incidence-of-chronic-kidney-disease-from-1992-to-2021-an"
canonical_url: "https://medichelpline.com/clinical-feed/plos-one-20-temporal-trends-in-the-incidence-of-chronic-kidney-disease-from-1992-to-2021-an"
content_type: "clinical_feed_article"
specialty: "Nephrology"
source_name: "PLOS ONE (Medicine)"
source_url: "https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0362853"
published_at: "2026-11-16T14:00:00.000Z"
evidence_level: "Journal Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Global and Regional Trends in Chronic Kidney Disease Incidence, 1992–2021, with Projections to 2031
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/plos-one-20-temporal-trends-in-the-incidence-of-chronic-kidney-disease-from-1992-to-2021-an
- **Specialty:** [Nephrology](https://medichelpline.com/clinical-feed/nephrology.md)
- **Primary Source:** PLOS ONE (Medicine)
- **Source URL:** [Original Journal Publication](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0362853)
- **Published At:** 2026-11-16T14:00:00.000Z
- **Evidence Rating:** Journal Feed
## Executive GIST (TL;DR)
- The investigators used GBD 2021 incidence counts and age-standardized incidence rates (**ASIR**) to analyze CKD trends for adults aged 20–79 years across 1992–2021 and to forecast to 2031. - An age-period-cohort (**APC**) model produced net drift (overall annual change), local drift (age-specific annual change), and period/cohort relative risks (RR); a univariate **ARIMA** time-series model produced ten-year ASIR forecasts. - Global incident CKD cases rose from 8.24 million in 1992 to 19.94 million in 2021 (a 141.99% increase). The global **ASIR** increased from 194.74 to 233.56 per 100,000 over the same interval. - The APC net drift globally was 0.79% per year (95% CI: 0.76%–0.83%); net drift varied by SDI region, lowest in high SDI (0.34%/yr) and highest in middle SDI (1.06%/yr). - Age effects: within cohorts, CKD risk rose with advancing age; local drift declined slightly after age 60 (e.g., 0.76% at 60–64 to 0.68% at 75–79). - Period and cohort effects increased over time and across later birth cohorts respectively, with cohort RRs >1 for cohorts born after the 1957–1961 reference. - The ARIMA projection estimated global **ASIR** of 237.91 (95% CI: 227.54–248.28) per 100,000 by 2031; regional projections showed an overall rise except a projected net decrease in the high SDI region. - The source reported specific regional projections for high and middle SDI regions but the provided source text was truncated and did not include the complete numeric projections for low-middle and low SDI regions. - All analyses used mean GBD point estimates; the APC and ARIMA model CIs reflect model uncertainty only and do not propagate GBD draw-level uncertainty. - The study excluded people <20 and ≥80 years, used ICD-11 GB61 for CKD, and did not incorporate covariates into ARIMA forecasting according to the authors.
## Clinical Analysis & Structured Key Points
Temporal trends in the incidence of chronic kidney disease from 1992 to 2021: An age-period-cohort analysis using GBD 2021 data and projections until 2031 | PLOS One Browse Subject Areas ? Click through the PLOS taxonomy to find articles in your field. For more information about PLOS Subject Areas, click here . Article Authors Metrics Comments Media Coverage Reader Comments Figures Figures Abstract Background This study analyzed the temporal trends in the incidence of Chronic kidney disease (CKD) globally and across various regions over the past 30 years, as well as projected incidence for the next 10 years. These findings may help identify regions and age groups where intensified CKD surveillance, prevention, and health-system planning should be prioritized. Methods Data on the number of CKD cases and age-standardized incidence rates (ASIR) were obtained from the GBD 2021 dataset. The age, period, and cohort effects were assessed using the age-period-cohort (APC) model. Subsequently, a univariate autoregressive integrated moving average (ARIMA) model was developed based on the historical incidence time series to forecast incidence trends up to the year 2031. Results Globally, CKD incident cases rose from 8.24 million in 1992 to 19.94 million in 2021, representing a 141.99% increase (2.42-fold growth). The ASIR increased from 194.74 to 233.56 per 100,000, with an annual net drift of 0.79%. Among the different socio-demographic index (SDI) regions, net drift was lowest in high SDI regions(0.34% per year) and highest in middle SDI regions(1.06% per year). Age, period, and cohort effects demonstrated similar trends globally and across SDI regions: CKD risk increased with age, period and birth cohort. The ARIMA model projected global ASIR to reach 237.91 (95% CI: 227.54–248.28) per 100,000 by 2031. Except for a slight decrease in the high SDI region, an increasing trend was observed in the other four SDI regions. Conclusion This study suggests that the burden of CKD incidence increased over the past 30 years and could continue to rise in the coming decade. The middle SDI regions may warrant particular concern. Citation: Zheng Y, Wei M, Lu D, Liu Y, Chen X, Mi J, et al. (2026) Temporal trends in the incidence of chronic kidney disease from 1992 to 2021: An age-period-cohort analysis using GBD 2021 data and projections until 2031. PLoS One 21(11): e0362853. https://doi.org/10.1371/journal.pone.0362853 Editor: Wisit Kaewput, Phramongkutklao College of Medicine, THAILAND Received: July 3, 2025; Accepted: October 31, 2026; Published: November 16, 2026 Copyright: © 2026 Zheng et al. This is an open access article distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Data Availability: Data supporting the findings of this study were obtained from the Global Burden of Disease (GBD) database. These data can be found here: https://vizhub.healthdata.org/gbd-results/ . Funding: This work was supported by the Postgraduate Scientific Research Innovation Program Project of Bengbu Medical University (No. Byycx24110), the Key Project of Natural Science of Education Department of Anhui Province (No. 2022AH051425), the Key Project of Natural Science of Education Department of Anhui Province (No. KJ2021A0710) and the Key Project of Natural Science of Bengbu Medical College (No. 2020byzd044). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Competing interests: The authors have declared that no competing interests exist. 1. Background Chronic kidney disease (CKD) is a significant public health concern, defined as abnormalities of kidney structure or function present for at least 3 months, with adverse health consequences [ 1 ]. CKD is widespread, affecting approximately 8–16% of the global population [ 2 ]. In 2004, a prevalence of 13.1% among adults in the United States was reported, and has continued to rise [ 3 ]. Globally, approximately 843.6 million individuals were affected by CKD in 2017 [ 4 ]. Moreover, CKD has emerged as one of the leading causes of mortality. It remains among the few noncommunicable diseases for which mortality rates have increased over the past two decades [ 5 ]. CKD burden varies across regions, and these variations may relate to differences in socioeconomic development and healthcare capacity [ 6 ]. High SDI regions have the highest age-standardized CKD incidence rates due to diabetes and hypertension epidemics, yet show the slowest annual growth owing to universal screening and well-resourced nephrology systems [ 7 ]. In contrast, middle SDI regions face the fastest-growing burden globally, driven by factors such as population aging, environmental exposure, and limited screening coverage [ 8 ]. Low-middle and low SDI regions display lower crude ASIR, which may reflect underdiagnosis rather than true low disease prevalence; a considerable proportion of patients with advanced CKD in these regions may lack access to dialysis or transplantation, contributing to notably high CKD-attributable premature death and DALY [ 9 ]. Collectively, middle, low-middle, and low SDI regions account for a considerable proportion of the global CKD burden, where gaps remain in early detection, risk factor control, and renal replacement therapy capacity [ 10 ]. CKD can lead to various adverse clinical outcomes, particularly cardiovascular diseases [ 11 ]. Recent studies indicate that patients with moderate to severe CKD undergoing hemodialysis are at significantly higher risk of cardiogenic sudden death, which remains one of the primary causes of mortality in this population [ 12 , 13 ]. The development of CKD is closely associated with various risk factors, such as hyperglycemia [ 5 ] and hypertension [ 14 ]. Early detection and intervention can significantly improve renal and cardiovascular outcomes [ 15 ]. The International Society of Nephrology has called for a global focus on the prevention and control of kidney diseases. However, in many regions, the burden of CKD remains inadequately addressed [ 16 ]. The Global Burden of Disease (GBD) 2021 [ 17 ] provides a comprehensive assessment of the burden of CKD. This study, utilized GBD 2021 data to examine temporal changes in CKD incidence and predict future trends globally and across different socio-demographic index (SDI) regions. The age-period-cohort (APC) model was employed to analyze temporal progression, and the autoregressive integrated moving average (ARIMA) model was used to forecast age-standardized incidence rates (ASIR) worldwide and in the five SDI regions up to 2031. The primary objective was to provide comprehensive insights into the effects of age, period, and cohort on CKD incidence, thereby identifying potential prevention strategies and directions for future research. 2. Methods 2.1 Data sources and case definitions In this study, the International Classification of Diseases, 11th edition (ICD-11) code GB61 was utilized as the standardized definition for CKD. The data used in this study were sourced from the Global Burden of Disease (GBD) 2021 study. GBD is a global research initiative led by the Institute for Health Metrics and Evaluation and provides a comprehensive empirical assessment of global health [ 18 ]. GBD 2021 summarizes the disease burden of 371 diseases and injuries across 204 countries and regions from 1990 to 2021, including metrics such as incidence, prevalence, and disability-adjusted life years, which are disaggregated by age groups and gender [ 19 ]. 2.2 Study population This study excluded individuals under 20 years of age. First, the etiologies of CKD in children and adolescents differ substantially from those in adults, with pediatric cases primarily attributable to congenital abnormalities (such as renal dysplasia) and hereditary diseases (such as Alport syndrome). In contrast, adult CKD is predominantly caused by acquired factors such as diabetes and hypertension [ 20 ]. Second, assessment of renal function in children requires specific formulas adjusted for age and height (such as the Schwartz formula), which are not directly comparable to adult standards, such as the CKD Epidemiology Collaboration (CKD-EPI) equation [ 21 ]. Patients aged over 80 years were also excluded, as this population often has multiple chronic conditions (such as heart failure and malignancies) that may confound independent evaluation of CKD progression [ 22 ]. Moreover, the age-related decline in muscle mass reduces the accuracy of estimated glomerular filtration rate (eGFR), limiting the validity of the model [ 22 , 23 ]. Therefore, twelve age groups were included: 20–24, 25–29, 30–34, 35–39, 40–44, 45–49, 50–54, 55–59, 60–64, 65–69, 70–74, and 75–79. All data were retrieved using the Global Health Data Exchange query tool [ 24 ]. 2.3 Estimation of incidence All CKD incidence counts and ASIR were extracted via GHDx stratified by year, age and SDI region. ASIR values pre-calculated with GBD 2021 global standard population were directly exported without manual recalculation. Changes in the ASIR from 1992 to 2021 are presented as percentage variations. GBD generates 1,000 posterior uncertainty draws for each subgroup. The 2.5th and 97.5th percentiles of draws formed the 95% UI for raw burden metrics. For the APC decomposition and ARIMA forecasting analyses, only mean point estimates of incidence and ASIR were used as fixed inputs. Accordingly, 95% CIs generated from APC and ARIMA models reflect only statistical uncertainty originating from the regression and time‑series modelling procedures, and do not propagate draw‑level uncertainty from the underlying GBD estimates. Statistical significance for APC-derived estimates was assessed using the appropriate null values (zero for drift estimates and one for relative risks), based on the corresponding 95% confidence intervals or Wald tests. The 95% uncertainty intervals of GBD estimates were reported descriptively and were not used for formal hypothesis testing. ASIR values are reported per 100,000 population. 2.4 Age-period-cohort model analysis The APC model [ 25 ] employs a log-linear Poisson regression [ 26 , 27 ]. The period effect reflects changes over time; the age effect reflects changes in disease rates with aging; and the cohort effect denotes variations across generations due to differential exposure to risk factors [ 27 ]. Age, period, and cohort are perfectly collinear (cohort = period-age) [ 28 ],which precludes unique parameter estimation [ 29 ]. To address this, we employed an approach based on estimable functions, constructing cohort deviations orthogonal to the cohort linear trend, thereby mitigating identifiability issues [ 27 ]. The APC analysis requires uniformly spaced 5-year periods to guarantee balanced cohort grouping and valid estimable function calculation. The time span 1992–2021 can be evenly divided into six complete non-overlapping 5-year intervals (1992–1996, 1997–2001, 2002–2006, 2007–2011, 2012–2016, 2017–2021). Data from GBD 2021 were reorganized by five-year age groups(20–24 to 75–79 years) and six five-year periods(1992–2021), consistent with the APC model’s requirement for equal intervals, generating 17 partially overlapping 10-year birth cohorts(1912–1921 to 1992–2001). The estimable functions included net drift (overall annual percentage change in incidence), local drift (annual percentage change for specific age groups), and period and cohort relative risks (RR). Reference categories were automatically assigned to the central values by the web tool following Rosenberg et al [ 25 ]. The statistical significance of annual percentage change was assessed using the Wald χ 2 test. A p-value less than 0.05 was considered statistically significant. All analyses were conducted in R (version 4.4.1), using packages including magrittr, dplyr, and data.table. 2.5 Autoregressive integrated moving average model The ARIMA model captures the dynamic characteristics of a time series and facilitates prediction by applying differencing to nonstationary series in combination with autoregressive and moving average components [ 30 ]. Using GBD 2021 data, we constructed an ARIMA model with appropriate differencing. The optimal parameters (p, d, q) were selected based on the Akaike information criterion (AIC) using the “auto.arima()” function. The Ljung-Box test was applied to assess the serial correlation of the residuals [ 31 ]; the resulting p-value was greater than 0.05, indicating the model passed the white noise test. To evaluate predictive performance and statistical uncertainty, the “auto.arima()” function generated 95% CI. The purpose of this study is to elucidate the inherent temporal pattern of CKD incidence and to construct a ten-year baseline prediction model exclusively grounded in historical incidence dynamics. Accordingly, the analytical framework did not incorporate any covariates or risk factors influencing changes in incidence. 2.6 Ethics statement All analyses in this study were based on publicly available, anonymized summary data from the Global Burden of Disease (GBD 2021) study. As these data contain no personal identifying information, ethical approval was not required for this study. 3. Results 3.1 Global, regional, and age-based trends Table 1 summarizes the incidence numbers, ASIR, and net drift of CKD globally and across the five SDI regions for 1992 and 2021. Globally, the incidence number increased from 8,243,753.16 (95% UI: 7,660,231.19 to 8,880,994.12) in 1992–19,935,037.76 (95% UI: 18,702,792.56 to 21,170,794.11) in 2021. Correspondingly, the ASIR rose from 194.74 (95% UI: 181.24 to 209.90) to 233.56 (95% UI: 220.02 to 247.24) per 100,000 population. This was consistent across all five SDI regions ( Table 1 ). The long-term temporal trend, quantified by the net drift (annual percentage change) from the APC model, further confirmed a steady increase in global CKD incidence, with an average annual increase of 0.79% (95% CI: 0.76% to 0.83%). All SDI regions exhibited positive net drifts ( Fig 1 ), indicating sustained growth, but with distinct patterns. Notably, the high SDI regions had the highest ASIR in 2021 [277.75 (95% UI: 260.70 to 295.01) per 100,000] but the lowest net drift [0.34% (95% CI: 0.27% to 0.40%)], whereas the middle SDI regions showed the most rapid increase, with the highest net drift of 1.06% (95% CI: 1.02% to 1.10%). The low SDI regions had the lowest ASIR in 2021 [155.00 (95% UI: 143.40 to 167.34) per 100,000], with a net drift of 0.60% (95% CI: 0.57% to 0.63%). Download: PNG larger image TIFF original image Table 1. Global and SDI trends in CKD incidence from 1992–2021. https://doi.org/10.1371/journal.pone.0362853.t001 Download: PNG larger image TIFF original image Fig 1. Incidence of CKD, 1992–2021. (A) Incidence numbers; (B) ASIR. Abbreviations: CKD, chronic kidney disease; ASIR, age-standardized incidence rates. https://doi.org/10.1371/journal.pone.0362853.g001 The age-stratified analysis revealed nuanced patterns in the annual percentage change (local drift) of CKD incidence ( Fig 2 ). Globally, a slight deceleration in the rate of increase was observed with advancing age. While incidence trends remained relatively stable from ages 25–29 to 55–59 years, a gradual decline in the local drift was evident after age 60, decreasing from 0.76% (95% CI: 0.72% to 0.80%) at 60–64 years to 0.68% (95% CI: 0.62% to 0.74%) at 75–79 years. Regional variations in age-specific trends were pronounced. In high SDI regions, the increase in incidence rates across all age groups was below the global average. The most substantial increase in these regions was seen in the 35–39 age group, with a local drift of 0.58% (95% CI: 0.44% to 0.72%). Conversely, middle SDI regions consistently exhibited growth trends exceeding the global average across all age groups. Even the lowest annual local drift in these regions, observed in the 30–34 age group [0.94% (95% CI: 0.84% to 1.05%)], was higher than the global net drift. Across all SDI regions, the upward trend in incidence generally became more pronounced after age 65. Download: PNG larger image TIFF original image Fig 2. Local drift of incidence from 1992–2021 for CKD for twelve age groups. The dots and shaded areas denote the local drift and their corresponding 95% CI. Abbreviations: CKD, chronic kidney disease; CI, confidence intervals. https://doi.org/10.1371/journal.pone.0362853.g002 3.2 Age, period and birth cohort effects Figure 3 and Table 2 show the age, period, and birth cohort effects at the global level and across five SDI regions, as estimated by the APC model. Download: PNG larger image TIFF original image Table 2. The wald χ 2 test of age, period and cohort effects. https://doi.org/10.1371/journal.pone.0362853.t002 Download: PNG larger image TIFF original image Fig 3. Age, period and cohort effects on CKD incidence according to the APC models. (A) Age effects are depicted by age-specific longitudinal rates that are adjusted for changes in different birth cohorts, taking into account period-specific biases. (B) Period effects are shown by the RR of CKD incidence over time, which is shown as the ratio of age-specific rates from 1992–1996 to 2017–2021, with the baseline period set to 2002–2006. (C) Birth cohort effects was evidenced by cohort relative incidence rates and calculated as the ratio of age-specific rates from the 1917–1921 cohort to those from the 1997–2001 cohort, with the reference cohort set to 1957–1961. Dots and shaded areas indicate incidence or rate ratios and their corresponding 95% CI. Abbreviations: CKD, chronic kidney disease; APC: age-period-cohort; RR: relative risks; CI: confidence intervals. https://doi.org/10.1371/journal.pone.0362853.g003 Age effects: Overall, the age effect showed a similar pattern globally and across SDI regions, with the risk of developing CKD within the same birth cohort increasing with age. When sequencing from high to low SDI regions, the incidence of CKD gradually decreased. Period effects: Globally and in SDI regions, the risk of incidence slowly increased over the study period. Compared with the reference period (2002–2006), the disease risk was lower during 1992–1996 and 1997–2001 for high-middle, middle, and low-middle SDI regions, and increased after 2006. In low SDI regions, although the incidence risk gradually decreased from 1992 to 2001, it remained higher than that in the reference period. Birth cohort effects: Consistent trends were observed globally and across SDI regions. The risk of CKD increased with later birth cohorts. Compared with the 1957–1961 reference cohort, subsequent birth cohorts presented incidence rate ratios significantly greater than 1. 3.3 Prediction in the next decade The prediction of ASIR globally and in five SDI regions was shown in Fig 4 . The optimal model parameters, along with their corresponding AIC, Bayesian information criterion (BIC), Ljung–Box test p-values and ARIMA (p,d,q), are detailed in Table 3 . The global ASIR of CKD is projected to exhibit a steady upward trend over the next decade, increasing from 233.56 per 100,000 in 2021 to 237.91 (95%CI: 227.54–248.28) per 100,000 in 2031. In high SDI regions, the ASIR is expected to initially decrease and then increase, falling from 277.75 per 100,000 in 2021 to 255.90 (95%CI: 240.06–271.75) per 100,000 in 2027 and subsequently increasing to 275.92 (95%CI: 255.17–296.68) per 100,000 in 2031, indicating an overall downward trend over the next decade. Significant increases are anticipated across other regions.The Middle SDI region shows the largest increase, from 232.96 per 100,000 in 2021 to 252.36 (95%CI: 246.58–258.14) per 100,000 in 2031. The ASIR in low-middle SDI and low SDI regions are expected to increase at a slower pace, rising from 204.97
## Related Clinical Research

- [Meta-analysis addendum: Revised trial-level links between GFR slope and kidney failure](https://medichelpline.com/clinical-feed/nature-0-addendum-a-meta-analysis-of-gfr-slope-as-a-surrogate-endpoint-for-kidney-failure.md)
- [Risk Factors for Progressive Cardiorenal Syndrome in CKD: Findings from the CRIC Cohort](https://medichelpline.com/clinical-feed/medrxiv-1-risk-factors-for-progressive-cardiorenal-syndrome-events-in-patients-with.md)
- [Prevalence, risk factors, and renoprotective treatment gaps in chronic kidney disease among tertia](https://medichelpline.com/clinical-feed/bmj-open-9-prevalence-risk-factors-and-renoprotective-treatment-of-chronic-kidney-disease.md)
- [Cardiovascular risk and mortality after statin initiation: achieved LDL and non‑HDL levels in a 3‑](https://medichelpline.com/clinical-feed/plos-medicine-0-risk-of-cardiovascular-events-and-mortality-associated-with-ldl-and-non-hdl.md)
- [ZEUS trial: IL-6 blocker ziltivekimab lowered inflammation but did not cut major CV events](https://medichelpline.com/clinical-feed/aha-news-1-researchers-say-inflammation-as-a-treatment-target-still-important-despite.md)

## Navigation
- [← Back to Nephrology Feed](https://medichelpline.com/clinical-feed/nephrology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.